Discover the phage display platform that made it possible
 
Antibody Library
Step 1: Immune COVID-19 Library Construction

> Isolation of peripheral blood mononuclear cells (PBMC) sourced from a COVID-19 survivor
> Construction of a fully human scFv antibody library

Milestone: scFv library diversity of > 109
Phage Display
Step 2: Antibody Phage Display

> Library enrichment via phage display using the receptor-binding domain (RBD) of SARS-CoV-2 variant Alpha
> Identification of clones able to cross-react with all other major variants
> Competitive ELISA using Alpha’s RBD and the human ACE2 receptor

Milestone: isolation of 9 cross-reactive + neutralizing binders
Recombinant Expression
Step 3: Recombinant Expression

> Fast recombinant expression in XtenCHO™ to characterize the bioactivity and stability of binders

Milestone: all but 1 binder displayed high activity and stability
Neutralizing Activity
Step 4: Testing for Neutralizing Activity Against Major Variants

> Rapid screening using ProteoGenix’s SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit
> Validation of the bioactivity via Plaque Reduction Neutralization Tests (PRNT)

Milestone: identification of 4 mAbs with strong neutralizing activity against all variants
Inhibition of SARS-CoV-2 by antibodies of the new cocktail
Inhibition (%) of major variants of SARS-CoV-2 by each individual antibody of the AH-5-COV cocktail determined via PRNT test
Aseem Healthcare & Trident Biopharm Solutions
“I requested ProteoGenix’s services for the generation of neutralizing anti-COVID-19 antibodies by Phage Display.

They designed an optimised strategy for this purpose which led to great results, with 4 antibodies identified as cross-reactive and neutralizing against all the current variants of concerns.

During the whole project, Proteogenix strived to ensure the best quality of their final deliverables, especially by including additional screenings against emerging variants as the pandemic evolved.

Their proactivity was key to obtaining promising and relevant blocking antibodies in only a few months. I highly recommend them for both their level of expertise and the personalised service they offer.”


Khelan Patel
Managing Director
Trident Biopharm Solutions, London, UK
7 Weeks
Get the best functional binders for your target in as little as 7 weeks
300+ projects
Benefit from the expertise gathered from 300+ successful phage display campaigns
3 licensed mAbs
Choose a platform that prioritizes developability to minimize risks and accelerate time to market